Growing Globally And Tapping Expertise: Tales From Bio Korea

 
• By Carole Goldsmith

South Korea’s Boryung Pharm has now signed $1 billion worth of global agreements for its antihypertensive Kanarb, while U.S. regenerative medicine company Orgenesis, which is working to cure type 1 diabetes with technology that combines cellular and regenerative therapy, has signed collaborative deals with two Korean partners, a recent meeting in Seoul heard.

With sales now spanning the globe, Boryung Pharmaceuticals Co. Ltd. has developed Kanarb (fimasartan) partnerships with China’s Harbin Gloria Pharmaceuticals Co. Ltd., Russia’s R Pharma, Brazil’s Ache Laboratorios and with Stendhal Pharma to supply 12 countries in Mexico and Latin America.

It also has deals to sell the angiotensin renin blocker (ARB) across the EU, Association of South East Asian Nations...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.